Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma × aumolertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 18 Lung Neoplasms 7 Brain Neoplasms 4 Rare Tumor 1 Radiation Pneumonitis 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1 Meningeal Carcinomatosis 1 EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1 Carcinoma 1 Advanced Non-small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 17 Gemcitabine 15 pembrolizumab 14 Radiotherapy 13 Paclitaxel 13 Radiotherapy, Intensity-Modulated 12 Carboplatin 10 Cyclophosphamide 9 Cetuximab 8 Magnetic Resonance Spectroscopy 7 Specimen Handling 6 Oxaliplatin 6 Fluorouracil 6 Docetaxel 6 Capecitabine 6 padeliporfin 5 Radiation 5 Irinotecan 5 Drug Therapy 5 poly ICLC 4 fludarabine 4 anlotinib 4 Standard of Care 4 Nivolumab 4 Leucovorin 4 Ipilimumab 4 Celecoxib 4 durvalumab 3 Sunitinib 3 Sorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Recruiting

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡